Molecular and Genetic Medicine

Leptomeningeal dissemination (LM) is a major complication of a systemic cancer. In this paper, we will present a rare case of LM as the first presenting feature of an unknown primary. The patient had a good response to systemic corticosteroids for a week but, surprisingly, after investigation, the primary tumor was suspected to be a gastric tumor. Sadly, the patient died a few days later. In a literature search, it was hard to find similar cases, and the suggested protocols are very vague about LM from an unknown tumor. This case demonstrates that LM can be the first presentation of a systemic tumor, raising questions on treatment with corticosteroids.

Introduction: The aim of this review is to hypothesize the mechanism of action of chlorine dioxide in COVID-19 by studying its mechanism of action in the structure of SARS-CoV-2.

Methods: Reviews of research on the mechanism of action of chlorine dioxide in viruses, particularly SARS-CoV-2and influenza viruses at the amino acid level in the viral spike were conducted and these data were transferred to the same structural amino acids of SARS-CoV-2. We used 3D computer reconstructions, use of data through cryo-electronic studies, and previous work based on ChimeraX (UCSF) augmented reality software.

Results: The projection and simulation of chlorine dioxide oxidation in structural amino acids of SARS-CoV-2 allows inferring the sites in which chlorine dioxide exerts a denaturalizing action on viral structure and on human ACE2 as well as it is possible to understand the extreme speed with which it acts, which could explain the first findings of clinical observational studies of chlorine dioxide use in COVID-19 carried out by the authors in Bolivia under strict compliance of ethics committee.

Conclusion: The oxidation by chlorine dioxide of critical amino acids in the spike of the coronavirus SARS-CoV-2 and in the structure of ACE2 allows us to understand the potentially therapeutic actions of chlorine dioxide dissolved in water by oral way in the COVID-19. We hope to publish clinical application trials of this promising systemic virucide soon.